View Older Stories View More Recent Stories

May 8, 2023 02:45PM Merck Announces Global Grants Program To Improve Access to Quality Health Care in Underserved Communities
May 1, 2023 05:24AM Merck (MRK) Provides Update on Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
Apr 28, 2023 05:30PM Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
Apr 27, 2023 06:30AM Merck Announces First-Quarter 2023 Financial Results
Apr 16, 2023 12:06PM Merck's (MRK) KEYTRUDA plus chemo 'significantly' improves overall survival in binary tract cancer
Apr 16, 2023 11:00AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
Apr 16, 2023 10:17AM Merck (MRK) to acquire Prometheus Biosciences Inc. (RXDX) for $200/share
Apr 16, 2023 06:00AM Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Apr 16, 2023 06:00AM Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Apr 13, 2023 06:46AM Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
Apr 13, 2023 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
Apr 11, 2023 01:20PM Merck Named One of Fortune’s 2023 100 Best Companies to Work For(R)
Apr 10, 2023 05:49AM Merck (MRK) and Eisai Provide Update on Phase 3 Trials of KEYTRUDA Plus LENVIMA
Apr 10, 2023 05:48AM Moderna (MRNA) and Merck (MRK) Report MRNA-4157/V940 in Combination With Keytruda Received Prime Scheme Designation in EU
Apr 7, 2023 06:45AM Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-
Apr 3, 2023 05:01PM FDA Approves Merck’s (MRK) KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Apr 3, 2023 05:00PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Can
Mar 30, 2023 06:45AM Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
Mar 29, 2023 04:15PM Merck (MRK) Announces FDA Converts to Full Approval Indication for KEYTRUDA for MSI-H
Mar 29, 2023 04:15PM FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMM
Mar 27, 2023 05:18PM Merck (MRK) Reports KEYTRUDA Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Mar 27, 2023 05:15PM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Rega
Mar 27, 2023 08:00AM Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
Mar 16, 2023 04:08PM Merck (MRK) Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial of MK-7684A
Mar 16, 2023 04:05PM Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small
Mar 10, 2023 06:45AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Mar 8, 2023 06:45AM Merck to Present at the Barclays 2023 Global Healthcare Conference
Mar 6, 2023 12:01PM Merck (MRK) Announces Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Mar 6, 2023 12:01PM Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Backgroun
Mar 6, 2023 12:00PM Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
Mar 6, 2023 06:45AM Merck (MRK) Announces FDA Approval of Intramuscular Administration of MMRV Family of Vaccines
Mar 6, 2023 06:45AM US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measl
Mar 2, 2023 09:04AM Merck (MRK) and AstraZeneca (AZN) Provide Update on US Regulatory Review of LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone
Mar 2, 2023 09:00AM Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-
Mar 1, 2023 06:45AM Merck (MRK) Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS)
Mar 1, 2023 06:45AM Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Feb 28, 2023 06:46AM Merck (MRK) Issues Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
Feb 28, 2023 06:45AM Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
Feb 24, 2023 06:49AM Merck (MRK) and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO
Feb 24, 2023 06:49AM Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
Feb 22, 2023 06:47AM Merck (MRK) Opens Enrollment in New Phase 3 Trials with Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Feb 22, 2023 06:45AM Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Feb 21, 2023 06:45AM Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
Feb 21, 2023 06:41AM Merck (MRK) Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO
Feb 21, 2023 06:40AM Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
Feb 17, 2023 06:45AM Merck (MRK) Announces FDA Acceptance for Priority Review of sNDA for PREVYMIS in Cytomegalovirus Disease in Kidney Transplant Recipients
Feb 17, 2023 06:45AM U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
Feb 16, 2023 12:30PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adeno
Feb 16, 2023 10:01AM Merck (MRK) and AstraZeneca (AZN) Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial
Feb 16, 2023 10:00AM Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
View More Recent Stories View Older Stories